Caris tissue-based profiling utilizes the most advanced technologies and comprehensive approach to analyze DNA, RNA and proteins to reveal a molecular blueprint that guides more precise and individualized treatment decisions that leads to improved patient outcomes.
Microdissection isolates specific tumor cells for testing
and reduces non-cancer material diluting the tissue section.
Case 1 – Extract the most clinically relevant content: Helps maximize the clinical utility of every tissue sample.
Case 2 – Limited tissue capabilities: Tumor enrichment to maximize available specimen for limited tissue cases.
* In a 2018 comparison of Tumor Mutational Burden (TMB) in NSCLC the Foundation Medicine Checkmate 2271 success rate2 was 60.9% compared to a success rate of 85.1% for Caris3, due in large part to the tissue microdissection enrichment at Caris Life Sciences.